Baseline Liver Function and Subsequent Outcomes in the Phase 3 REFLECT Study of Patients with Unresectable Hepatocellular Carcinoma.

ABSTRACT:

Introduction

Baseline liver function among patients starting treatment for unresectable hepatocellular carcinoma (uHCC) impacts survival and could impact efficacy outcomes and safety profiles of treatments. This post hoc analysis of the phase 3 REFLECT study examined the efficacy and safety outcomes for lenvatinib and for sorafenib in patients with uHCC, assessed by Child-Pugh score (CPS) and albumin-bilirubin (ALBI) grade.

Methods

Efficacy and safety were assessed in patient cohorts from REFLECT according to study entry baseline ALBI grade and CPS.

Results

Lenvatinib treatment generally provided survival benefits in all groups. Median overall survival (OS) among patients with an ALBI grade of 1 was consistently higher than among patients with an ALBI grade of 2 for b

SUBMITTER: Vogel A 

PROVIDER: S-EPMC8527908 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature